Aquinox Pharmaceuticals has begun dosing patients in a Phase II trial of its lead clinical candidate, AQX-1125, a SHIP1 activator, for the treatment of exacerbations of chronic obstructive pulmonary disease (COPD). The multinational trial is being conducted at outpatient clinics across northern and central Europe and will evaluate the safety and efficacy of AQX-1125 in approximately 350-400 unstable moderate to severe COPD patients with a history of frequent exacerbations. The company has receiv...